SUCCESS RATES OF
TARGETED THERAPY
A single quoted response rate without context is noise dressed as data. The number that matters describes your specific mutation, drug, and disease stage -- not the average of a mixed population.
Key Targeted Therapy Response Rates
EGFR-mutant NSCLC -- Osimertinib first-line
BRAF V600-mutant Melanoma -- BRAF/MEK combination
HER2+ Metastatic Breast Cancer -- T-DXd (Enhertu)
Chronic-phase CML -- BCR-ABL inhibitors
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want Context-Specific Success Rate Data for Your Mutation and Stage?
CancerFax provides mutation-specific, stage-specific response data and connects you with oncologists who can explain what it means for your individual case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.